9. Pharmacological Therapy of Neuroendocrine Tumors

Shepherd J.J. , Senator G.B. : Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201–995. Lancet, 2: 574–576, 1986.

Susini C. , Buscail L. : Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol, 17: 1733–1742, 2006.

Saltz L. , Trochanowski B. , Buckley M. , Heffernan B. , Niedzwiecki D. , Tao Y. , Kelsen D. : Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 72: 244–248, 1993.

Arnold R. , Trautmann M.E. , Creutzfeldt W. , Benning R. , Benning M. , Neuhaus C. , Jürgensen R. , Stein K. , Schäfer H. , Bruns C. , Dennler H.J. : Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut, 38: 430–438, 1996.

Di Bartolomeo M. , Bajetta E. , Buzzoni R. , Mariani L. , Carnaghi C. , Somma L. , Zilembo N. , di Leo A. : Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer, 77: 402–408, 1996.

Eriksson B. , Renstrup J. , Imam H. , Oberg K. : High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol, 8: 1041–1044, 1997.

Ducreux M. , Ruszniewski P. , Chayvialle J.A. , Blumberg J. , Cloarec D. , Michel H. , Raymond J.M. , Dupas J.L. , Gouerou H. , Jian R. , Genestin E. , Hammel P. , Rougier P. : The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol, 95: 3276–3281, 2000.

Aparicio T. , Ducreux M. , Baudin E. , Sabourin J.C. , De Baere T. , Mitry E. , Schlumberger M. , Rougier P. : Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer, 37: 1014–1019, 2001.

Shojamanesh H. , Gibril F. , Louie A. , Ojeaburu J.V. , Bashir S. , Abou-Saif A. , Jensen R.T. : Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer, 94: 331–343, 2002.

Panzuto F. , Di Fonzo M. , Iannicelli E. , Sciuto R. , Maini C.L. , Capurso G. , Milione M. , Cattaruzza M.S. , Falconi M. , David V , Ziparo V. , Pederzoli P. , Bordi C. , Delle Fave G. : Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol, 17: 461–466, 2006.

Rinke A. , Müller H-H , Schade-Brittinger C. , Klose K-J , Barth P. , Wied M. , Mayer C. , Aminossadati B. , Pape U-F , Bläker M. , Harder J. , Arnold C. , Gress T. , Arnold R. : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol, 27: 4656–4663, 2009.

Moertel C.G. , Kvols L.K. , O'Connell M.J. , Rubin J. : Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer, 68: 227–232, 1991.

Bajetta E. , Ferrari L. , Procopio G. , Catena L. , Ferrario E. , Martinetti A. , Di Bartolomeo M. , Buzzoni R. , Celio L. , Vitali M. , Beretta E. , Seregni E. , Bombardieri E. : Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors. Ann Oncol, 13: 614–621, 2002.

Kaltsas G.A. , Mukherjee J.J. , Isidori A. , Kola B. , Plowman P.N. , Monson J.P. , Grossman A.B. , Besser G.M. : Treament of advanced neuroendocrine tumors using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol, 57: 169–183, 2002.

Sun W. , Lipsitz S. , Catalano P. , Mailliard J.A. , Haller D.G. : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol, 23: 4897–4904, 2005.

Delaunoit Th , Ducreux M. , Boige V. , Dromain C. , Sabourin J.C. , Duvillard P. , Schlumberger M. , de Baere T. , Rougier P. , Ruffie P. , Elias D. , Lasser P. , Baudin E. : The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? Eur J Cancer, 40: 515–520, 2004.

Mitry E. , Baudin E. , Ducreux M. , Sabourin J-C , Rufié P. , Aparicio T. , Lasser P. , Elias D. , Duvillard P. , Schlumberger M. , Rougier P. : Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer, 81(8): 1351–1355, 1999.

Bajetta E. , Catena L. , Procopio G. , De Dosso S. , Bichisao E. , Ferrari L. , Martinetti A. , Platania M. , Verzoni E. , Formisano B. , Bajetta R. : Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumors? Cancer Chemother Pharmacol, 59: 637–642, 2007.

Saltz L. , Kemeny N. , Schwartz G. , Kelsen D. : A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer, 74: 958–961, 1994.

Hughes M.J. , Kerr D.J. , Cassidy J. , Soukop M. , MCGregor K. , Blackburn N. , Yosef H. , Kaye S.B. : A pilot study of combination therapy with interferon-α-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumors. Ann Oncol, 7: 208–210, 1996.

Janson E.T. , Ronnblom L. , Ahlstrom H. , Grander D. , Alm G. , Einhorn S. , Oberg K. : Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol, 3: 635–638, 1992.

Modlin I.M. , Kidd M. , Latich I. , Zikusoka M.N. , Shapiro M.D. : Current status of gastrointestinal carcinoids. Gastroenterology, 128: 1717–1751, 2005.

de Herder W.W. : Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract Res Clin Gastroenterol, 19: 705–715, 2005.

Öberg K. , Eriksson B. : Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol, 19: 753–781, 2005.

Öberg K. , Åkerström G. , Rindi G. , Jelic S. : On behalf of the ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21: v223–v227, 2010.

Eriksson B. , Annibale B. , Bajetta E. , Mitry E. , Pavel M. , Platania M. , Salazar R. , Plöckinger U. , and all other Mallorca Consensus Conference participants: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology, 90: 214–219, 2009.

Rinke A. , Müller H-H , Schade-Brittinger C. , Klose K-J , Barth P. , Wied M. , Mayer C. , Aminossadati B. , Pape U-F , Bläker M. , Harder J. , Arnold C. , Gress T. , Arnold R. : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol, 27(28): 4656–4663, 2009.

Öberg K. , Kvols L. , Caplin M. , Delle Fave G. , de Herder W. , Rindi G. , Ruszniewski P. , Woltering E.A. , Wiedenmann B. : Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15: 966–973, 2004.

Ricci S. , Antonuzzo A. , Galli L. , Ferdeghini M. , Bodei L. , Orlandini C. , Conte P.F. : Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol, 11: 1127–1130, 2000.

Solcia E. , Klöppel G. , Sobin L.H. : Histological typing of endocrine tumours, ed 2. WHO International Histological Classification of Tumours. Berlin, Springer, 2000.

Rindi G. , Klöppel G. , Ahlman H. : TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch, 449: 395–401, 2006.

Rindi G. , Klöppel G. , Couvelard A. : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch, 451: 757–762, 2007.

Akerström G. , Falconi M. , Kianmanesh R. , Ruszniewski P. , Plöckinger U. , and all other Mallorca Consensus Conference participants: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 90: 203–208, 2009.

Oberg K. , Jelic S. : Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol, 20(Suppl 4), 150–153, 2009.

Oberg K. , Jelic S. : Neuroendocrine bronchial and thymic tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up, Ann Oncol, 20 (Suppl 4), 147–149, 2009.

Soga J. : Carcinoids and their variant endocrinocarcinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res, 22: 517–530, 2003.

Modlin I.M. , Lye K.D. , Kidd M. : A 5-decade analysis of 13715 carcinoid tumors. Cancer, 97(4): 934–959, 2008.

Liu Y. , Liang H. , Liu N. , Zhang R.P. , Cui Q.H. : Relationship of biological behavior and the prognosis in gastric carcinoid. Zhonghua Wei Chang Wai Ke Za Zhi, 10(5): 472–475, 2007.

Khaled O. , Shebani M.D. , Wiley W. , Souba M.D. , Dianne M. , Finkelstein D. , Stark P.C. , Elgadi K.M. , Tanabe K.K. , Ott M.J. : Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg, 229(6): 815–830, 1999.

Soga J. : Early-stage carcinoids of the gastrointestinal tract. An analysis of 1914 reported cases. Cancer, 103(8): 1587–1595, 2005.

Moertel C.G. , Hanley J.A. : Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials, 2(4): 327–334, 1979.

Engstrom P.F. , Lavin P.T. , Moertel C.G. , Folsch E. , Douglass HO J.r. : Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol, 2(11): 1255–1259, 1984.

Bukowski R.M. , Johnson K.G. , Peterson R.F. , Stephens R.L. , Rivkin S.E. , Neilan B. , Costanzi J.H. : A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A southwest Oncology Group Study. Cancer, 60(12): 2891–2895, 1987.

Sun W. , Lipsitz S. , Catalano P. , Mailliard J.A. , Haller D.G. : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol, 23: 4897–4904, 2005.

Hage R. , Seldenrijk K. , de Bruin P. , van Swieten H. , van den Bosch J. : Pulmonary large-cell neuroendocrine carcinoma (LCNEC). Eur J Cardiothorac Surg, 23: 457–460, 2002.

Battafarano R.J. , Fernandez F.G. , Ritter J. , Meyers B.F. , Guthrie T.J. , Cooper J.D. , Patterson G.A. : Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg, 130(1): 166–172, 2005.

Iyoda A. , Hiroshima K. , Moriya Y. , Takiguchi Y. , Sekine Y. , Shibuya K. , Iizasa T. , Kimura H. , Nakatani Y. , Fujisawa T. : Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg, 82(5): 1802–1807, 2006.